<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-INR-17012152</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-07-26</date_registration>
      <primary_sponsor>Shanghai Tongji Hospital</primary_sponsor>
      <public_title>Clinical research of transplantation of functional scaffold seeded with mesenchymal stem cells for the treatment of traumatic spinal cord injury</public_title>
      <acronym />
      <scientific_title>Clinical research of transplantation of functional scaffold seeded with mesenchymal stem cells for the treatment of traumatic spinal cord injury</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-09-30</date_enrolment>
      <type_enrolment />
      <target_size>functional scaffold only:6;functional scaffold seeded with low dose of mesenchymal stem cells:6;functional scaffold seeded with moderate dose of mesenchymal stem cells:6;functional scaffold seeded with high dose of mesenchymal stem cells:6;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=20729</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>spinal cord injury</hc_freetext>
      <i_freetext>functional scaffold only:transplantation of functional scaffold only;functional scaffold seeded with low dose of mesenchymal stem cells:transplantation of functional scaffold seeded with low dose of mesenchymal stem cells;functional scaffold seeded with moderate dose of mesenchymal stem cells:transplantation of functional scaffold seeded with moderate dose of mesenchymal stem cells;functional scaffold seeded with high dose of mesenchymal stem cells:transplantation of functional scaffold seeded with high dose of mesenchymal stem cells;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Wei Xu</firstname>
        <middlename />
        <lastname />
        <address>389 Xincun Road, Putuo District, Shanghai, China</address>
        <city />
        <country1 />
        <zip>200065</zip>
        <telephone>+86 17301809358</telephone>
        <email>lorings@163.com</email>
        <affiliation>Shanghai Tongji Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Liming Cheng</firstname>
        <middlename />
        <lastname />
        <address>389 Xincun Road, Putuo District, Shanghai, China</address>
        <city />
        <country1 />
        <zip>200065</zip>
        <telephone>+86 13701959550</telephone>
        <email>chlm.d@163.com</email>
        <affiliation>Shanghai Tongji Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. T1-11complete spinal cord injury (ASIA spinal cord injury assessment grade A, proved by electrophysiology test and MRI, injury level will be confirmed by physical examination);
2. The glial scar after spinal cord injury less than 2cm (proved by MRI);
3. Male or female aged 18-60 years with acute or subacute spinal cord injury (less than 3 months, ASIA grade A), no improvement after rehabilitation training;
4. Good muscle condition, function of peripheral nerves should be normal;
5. Good general condition,function of major organs should be normal; major laboratory examinations should be normal;
6. No brain diseases or psychological diseases;
7. Good compliance and knowledge level, have an objective understanding  to the condition and prognosis of the disease.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Combined with diseases that affect the recovery of spinal cord injury or rehabilitation training;
2. Non thoracic spinal cord injury;
3. Incomplete spinal cord injury or undefined injury site and range;
4. No rehabilitation training after spinal cord injury;
5. Muscle atrophy or fibrosis;
6. Degeneration of peripheral nerve;
7. Allergic constitution;
8. Received immunomodulator or experimental drug treatment 60 days before the research;
9. Severe background diseases, diabetes, autoimmune diseases, tumor or severe high blood pressure;
10. Poor general condition, malfunction of major organs, intolerance of surgery;
11. MODS, sepsis associated organ failure assessment scoreâ‰¥12;
12. Routine laboratory examinations inadequate and at least 1 positive result of the blood test: HCV antibody, HIV antibody or HTLV-1 antibody;
13. Severe bleeding tendency or coagulation disorders;
14. surgical site inflammation or skin ulcer;
15. Pregnancy or lactation period;
16. Refuse to sign the informed consent form.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>vital signs;blood routine examination;blood biochemistry examination;urine routine examination;blood coagulation examination;urinary sediment examination;stool OB examination;syphilis test;ECG;chest X-ray examination;psychological test;ASIA spinal cord injury assesment;motor score of key muncles;sensory score of key sites;function independent measure;electromyography;electrophysiology;MRI examination;urodynamic test;spasm;pain;gene analysis of blood sample;immune factors test of blood sample;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shanghai shenkang hospital development center clinical science and technology innovation project</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>1990-01-01</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>